Loading
NYSEHealthcareDrug Manufacturers - General
Latest quote
$144.71
−$2.815 · -1.91%
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Previous close
$144.71
−$2.815 · -1.91%
Pre-market
$145.44
+$0.73 · +0.50%
Sep 11, 7:23 AM ET
Regular session · ET · Market data may be delayed.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Day range
Current $144.71
52-week range
Current $144.71
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
66
Undervalued
Sentiment
69
Bullish
Risk
19
Low Risk
Momentum
56
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Day range
Current $144.71
52-week range
Current $144.71
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 64.93B USD | 64.17B USD | 60.12B USD | 59.28B USD | 48.7B USD |
| Cost of goods sold | 18.2B USD | 15.19B USD | 16.13B USD | 17.41B USD | 13.63B USD |
| Gross profit | 46.73B USD | 48.98B USD | 43.99B USD | 41.87B USD | 35.08B USD |
| Research and development | 12.51B USD | 17.94B USD | 30.53B USD | 13.55B USD | 12.25B USD |
| Selling, general, and administrative | 10.73B USD | 10.1B USD | 9.88B USD | 9.67B USD | 9.4B USD |
| Operating expenses | 23.25B USD | 28.75B USD | 41.04B USD | 23.59B USD | 21.88B USD |
| Interest income | 343M USD | 415M USD | 365M USD | 157M USD | 36M USD |
| Interest expense | 1.36B USD | 1.27B USD | 1.15B USD | 962M USD | 806M USD |
| Depreciation and amortization | 5.84B USD | 4.5B USD | 3.87B USD | 3.91B USD | 3.21B USD |
| Operating income | 23.49B USD | 20.22B USD | 2.95B USD | 18.28B USD | 13.2B USD |
| Net income | 18.25B USD | 17.12B USD | 365M USD | 14.52B USD | 13.05B USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$158.12
9.27% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.24B0.45%2.3T USD0.03%$373.24-0.62%
Vanguard S&P 500 ETFVOO8.44B0.50%1.7T USD0.03%$696.65-0.60%
Schwab U.S. Dividend Equity ETFSCHD5.32B4.81%110.53B USD0.06%$33.99-0.29%
iShares Core S&P 500 ETFIVV4.67B0.55%839.6B USD0.03%$761.53-0.60%
State Street SPDR S&P 500 ETFSPY4.46B0.55%803.52B USD0.09%$757.83-0.60%
Vanguard Morningstar Value ETFVTV3.06B1.19%256.5B USD0.03%$222.36-0.70%
State Street Health Care Select Sector SPDR ETFXLV2.63B6.07%43.25B USD0.08%$165.66-0.55%
Vanguard Dividend Appreciation ETFVIG1.82B1.39%130.9B USD0.04%$237.73-0.46%Vanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOSchwab U.S. Dividend Equity ETFSCHDiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVState Street Health Care Select Sector SPDR ETFXLVVanguard Dividend Appreciation ETFVIGAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
